Skip to main content

Catalyst Calendar

Wed, Oct 7, 2026

1 updates

8:00 AM

Kyowa Kirin Highlights FDA Acceptance and Priority Review of BridgeBio's NDA for Oral Infigratinib for Children Living with Achondroplasia

kyowakirin.com

Tue, Sep 8, 2026

1 updates

8:00 AM

Kyowa Kirin Announces Topline Results from Phase 2 Global Study of KHK4951 Eye Drops for Neovascular Age-Related Macular Degeneration

Trial Results • Phase 2kyowakirin.com

Tue, Sep 1, 2026

1 updates

8:00 AM

Kyowa Kirin Announces Agreement with U.S. Administration to Reduce Treatment Costs for Americans

kyowakirin.com

Fri, Aug 21, 2026

1 updates

8:00 AM

Notice Regarding Changes in the C-Suite Executive Structure

kyowakirin.com

Mon, Aug 3, 2026

1 updates

8:00 AM

Announcement of Consolidated Financial Results Fiscal 2026 Second Quarter

kyowakirin.com